文献速递白血病

急性髓系白血病细胞膜包覆纳米颗粒用于癌症疫苗免疫治疗

Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy.
PubMed 文献 · Leukemia · 2021-11-29

本文开发了急性髓系白血病(AML)细胞膜包覆纳米颗粒(AMCNP)疫苗平台,将载有免疫刺激佐剂的纳米颗粒用白血病细胞膜材料包覆。体外和体内实验中AMCNP被抗原提呈细胞高效摄取并刺激抗原交叉提呈,疫苗接种显著增强抗原特异性T细胞扩增和效应功能。预防性接种可增强细胞免疫并对抗AML攻击,在AML缓解后接种模型中AMCNP疫苗较全白血病细胞裂解物疫苗显著提高生存率。

要点

  • AMCNP疫苗平台将佐剂纳米颗粒用白血病细胞膜包覆,共递送膜抗原与佐剂至抗原提呈细胞。
  • AMCNP在体外和体内被抗原提呈细胞高效摄取并刺激抗原交叉提呈。
  • AMCNP接种较对照疫苗显著增强抗原特异性T细胞扩增和效应功能,并在缓解后模型中较全细胞裂解物疫苗显著提高生存率。

核心结论

  • AMCNP保留了AML特异性抗原,引发增强的抗原特异性免疫应答,并对抗AML攻击提供治疗获益。

研究设计与样本

  • 研究开发了AML细胞膜包覆纳米颗粒(AMCNP)疫苗平台,将载有免疫刺激佐剂的纳米颗粒用白血病细胞膜材料包覆。
  • 使用表达膜结合鸡卵清蛋白作为模型抗原的鼠AML细胞系,在体外和体内评估AMCNP的摄取、抗原交叉提呈和T细胞应答。
  • 在AML攻击模型中评估预防性接种AMCNP的保护作用,并在AML缓解后接种模型中比较AMCNP与全白血病细胞裂解物疫苗的生存获益。

主要发现

  • AMCNP在体外和体内被抗原提呈细胞高效摄取并刺激抗原交叉提呈。
  • 与对照疫苗相比,AMCNP接种显著增强抗原特异性T细胞扩增和效应功能。
  • 预防性AMCNP接种增强细胞免疫并对抗AML攻击提供保护。
  • 在AML缓解后接种模型中,AMCNP接种较全白血病细胞裂解物疫苗接种显著提高生存率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cancer vaccines are promising treatments to prevent relapse after chemotherapy in acute myeloid leukemia (AML) patients, particularly for those who cannot tolerate intensive consolidation therapies. Here, we report the development of an AML cell membrane-coated nanoparticle (AMCNP) vaccine platform, in which immune-stimulatory adjuvant-loaded nanoparticles are coated with leukemic cell membrane material. This AMCNP vaccination strategy stimulates leukemia-specific immune responses by co-delivering membrane-associated antigens along with adjuvants to antigen-presenting cells. To demonstrate that this AMCNP vaccine enhances leukemia-specific antigen presentation and T cell responses, we modified a murine AML cell line to express membrane-bound chicken ovalbumin as a model antigen. AMCNPs were efficiently acquired by antigen-presenting cells in vitro and in vivo and stimulated antigen cross-presentation. Vaccination with AMCNPs significantly enhanced antigen-specific T cell expansion and effector function compared with control vaccines. Prophylactic vaccination with AMCNPs enhanced cellular immunity and protected against AML challenge. Moreover, in an AML post-remission vaccination model, AMCNP vaccination significantly enhanced survival in comparison to vaccination with whole leukemia cell lysates. Collectively, AMCNPs retained AML-specific antigens, elicited enhanced antigen-specific immune responses, and provided therapeutic benefit against AML challenge.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Johnson DT, Zhou J, Kroll AV, et al. Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy. Leukemia. 2021. PMID: 34845316. doi:10.1038/s41375-021-01432-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。